Rationale: Short-term β-adrenergic stimulation promotes contractility in response to stress but is ultimately detrimental in the failing heart because of accrual of cardiomyocyte death. Endogenous cardiac progenitor cell (CPC) activation may partially offset cardiomyocyte losses, but consequences of long-term β-adrenergic drive on CPC survival and proliferation are unknown.
β -adrenergic signaling regulates cardiac inotropy, lusitropy, and chronotropy, 1,2 mediated primarily by β1 and β2 adrenergic receptor (AR) subtypes present on adult cardiomyocytes. β1-ARs regulate cardiac contractility by signaling through Gα s and adenylyl cyclase, 3 but chronic stimulation increases myocyte apoptosis and necrosis. 4, 5 In contrast, β2-AR signaling antagonizes cardiomyocyte death 6, 7 and also exerts widespread influence over multiple cell types, including tissue progenitors and precursor cells, by regulating mobilization, differentiation, and proliferation. [8] [9] [10] [11] [12] Stimulation of β2-AR also promotes DNA synthesis via activation of extracellular signal-regulated kinase and phosphoinositide 3 kinase pathways in cardiac fibroblasts, 13, 14 but the influence of β-adrenergic signaling on the cardiac progenitor cell (CPC) population remains unknown.
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The postnatal heart undergoes substantial proliferation in the face of adrenergic drive after birth 15 during which neonatal cardiomyocytes predominantly express β2-AR. However, cardiomyocyte maturation leads to dominant expression of β1-AR concomitant with recession of postnatal adrenergic stimulation in the adult myocardium. 16, 17 Cardiomyopathic injury reactivates the adrenergic system that, although initially adaptive, eventually becomes cardiotoxic in the chronic setting. 18 The seemingly counterintuitive administration of pharmacological β-blockade, a negative inotrope, in patients with heart failure as the current standard of care improves cardiac performance and resensitizes the adrenergic system. 19, 20 Cardiac homeostasis is intimately tied to adrenergic signaling throughout our lifetime, but the impact of adrenergic stimulation on CPC survival and proliferation has not been assessed. Because CPCs contribute to ongoing myocyte replacement, 21 consequences of β-adrenergic drive on CPC biology have important implications for the reparative and regenerative potential of the pathologically injured myocardium.
Potentiation of myocardial function in the damaged heart depends on a delicate balance between promoting contractility without impairing cardiomyocyte survival and regeneration. Deciphering molecular signals that impair cellular replacement are an integral part of developing novel interventional therapeutic strategies to enhance myocardial healing. Recent studies assert that reactivation and involvement of endogenous repair processes are a critical part of stem cell-mediated therapy, 22, 23 and the deleterious consequences of long-term β-adrenergic hyperactivity are indisputable. 1, 18 In the present study, we reveal a direct relationship between the β-AR system and CPC biology. Results demonstrate that adrenergic drive is a double-edged sword that promotes CPC survival and proliferation via β2-AR before lineage commitment but transitions into a deleterious stimulus on acquisition of β1-AR upon maturation and sensitization to catecholamine stress. Therefore, the β-AR system is an important factor in CPC biology, which may account, in part, for the beneficial effects of long-term β-adrenergic blockade as a pharmacological intervention to enhance CPC response in the failing heart.
Methods

Cell Culture and Differentiation
CPCs are isolated from syngeneic male FVB mice and cultured for 3 weeks in cardiac stem cell media. 24 Differentiation is induced in CPCs by coculture with neonatal cardiomyocytes in a ratio of 1:40. 25 Human CPCs from Institutional Review Board-exempt samples of patients receiving left ventricular assist device implantation were isolated and cultured in human CPC media (details provided in the Online Data Supplement).
Lentiviral Transduction
Fluorescent ubiquitination-based cell cycle indicator (FUCCI) CPCs are transduced with Lv-PgK1-Fucci Orange (MKO2) and Lv-PgK1-Fucci Green (Az), whereas CPCs expressing green fluorescent protein (GFP; CPCe) are transduced with Lv-egfp to create stable cell lines (details provided in the Online Data Supplement).
Pharmacological Treatments
CPCs are serum starved overnight and treated with specific β2-agonist fenoterol (FEN; 1 µmol/L; Sigma Aldrich) for 2 hours in serum-free medium before CyQuant labeling, metabolic assays, and protein analysis. Serum-free preconditioning was performed to eliminate the effect of serum on CPC proliferation to rule out any additional factors that may influence CPC proliferation and concentrate only on the effect of the specific β2-agonist (FEN) on CPC proliferation. Optimal FEN concentration with the maximum proliferation was determined by performing a dose-response treatment. Specific β2-antagonist ICI 118, 551 (0.3 µmol/L; TOCRIS biosciences) and β1-antagonist metoprolol (1 µmol/L; Sigma Aldrich) are used for manipulation of adrenergic stimulation. Inhibitors of phosphoinositide 3 kinase LY294002 (20 µmol/L; Sigma Aldrich) and NO synthase L-NG-nitroarginine methyl ester (L-NAME) (100 µmol/L; Sigma Aldrich) are used to assess signal transduction downstream of adrenergic stimulation. FEN-induced proliferation in FUCCI CPCs is determined by serumstarving the cells overnight, followed by FEN treatment for 2 hours the following day in serum-free medium. Cells were allowed to recover for 6 hours in full medium before analysis. Control CPCs were kept in serum-free medium for 2 hours and then for 6 hours in recovery medium. CPCs treated with full medium were used to establish a positive control and were treated for 2 hours in full serum medium, followed by additional 6 hours of full medium treatment (see Online Data Supplement Methods). Isoproterenol (ISO; 1 µmol/L) treatment of CPCs to induce catecholamine stress was performed for 6 hours before flow cytometric analysis.
siRNA Transfection
Small interfering RNA (siRNA; 20 µmol/L) transfection is performed with cells plated in 6-well dishes and transfected with 3 µL of siRNA and 12 µL of Hi Perfect transfection reagent (Qiagen) in 85 µL of DMEM/F12 without serum. 26 
CyQuant and Metabolic Assay
CyQuant and 3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay of CPCs are performed by plating cells in quadruplicate (2000 cells/well) in 96-well plates, followed by incubation with CyQuant (Invitrogen) or 3-(4,5-Dimethylthiazole-2-yl)-2,5diphenyltetrazolium bromide reagent (Sigma, St Louis, Mo), as previously described. 22
Immunoblots
Immunoblotting is performed as described. 26 Details regarding sample preparation and antibodies are provided in the Online Data Supplement.
Quantitative Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction
Total RNA is isolated from frozen heart or cultured cells using Quick-RNA MiniPrep (Zymo Research) and reverse-transcribed into cDNA using iScript cDNA Synthesis kit (Bio-Rad). Quantitative reverse transcriptase polymerase chain reaction is performed on all samples in triplicate using iQ SYBR Green (Bio-Rad) according to the manufacturer's instructions. Primer sequences are provided in Online Table I .
Flow Cytometry
Cell death is measured by Annexin V staining (BD Biosciences) according to the manufacturer's instructions. Cytometry is performed using a BD FACSAria Flow Cytometer (BD Biosciences).
Animal Studies
Institutional Animal Care and Use Committee approval was obtained for all animal studies. Detailed experimental procedures are provided in the Online Data Supplement.
Immunohistochemistry
Immunocytochemistry, terminal deoxynucleotidyl transferase dUTP nick end labeling assays, and immunohistochemistry are performed as previously described 26 
Results
CPCs Express β2-AR in Conjunction With c-kit
c-kit+ CPCs expressed β2-AR but not β1-AR as evidenced by immunolabeling of adult mouse heart (3-month-old) sections ( Figure 1A and 1B), as well as cultured CPCs ( Figure 1C and 1D). Expression of β2-AR and without β1-AR in cultured CPCs normalized to expression in heart was confirmed by immunoblot analysis ( Figure 1E ) and quantitative reverse transcriptase polymerase chain reaction ( Figure 1F ). Comparable findings are observed with human CPCs isolated from patients receiving left ventricular assist device where β2-AR is observed in the absence of β1-AR expression by immunoblot ( Figure  1G ). CPCs expressing c-kit+/β2-AR+ were identified in myocardial sections of infarction (Online Figure 
β2-AR Mediates CPC Proliferation
CPCs were modified to express FUCCI reporter genes to monitor cell cycle progression from G1 to S/G2/M by measuring red versus green fluorescence, respectively 28 (Online Figure IIA-IIE). FUCCI CPCs show significant (P<0.004) increases in cell cycle entry after 1 µmol/L FEN treatment (11.1%) compared with vehicle-treated controls (4.2%), representing 2.6-fold increase over controls ( Figure 2A ). DNA synthesis indicative of proliferation is also increased in CPCs after treatment with FEN (1 µmol/L) at day 3 (P<0.001) relative to vehicle-treated CPCs as measured by CyQuant assay ( Figure 2B ). Conversely, proliferation is significantly reduced at 1 day (P<0.001) or 3 days (P<0.001) if FEN-mediated β2-AR stimulation is blocked by ICI 118, 551 antagonist ( Figure 2B ). Similarly, metabolic activity is increased in CPCs after FEN treatment at day 3 (P<0.001) and significantly declines with ICI 118, 551 treatment (P<0.001; Figure 2C ). Treatment with metoprolol, a specific β1-AR antagonist, did not affect cell proliferation or metabolic activity in the presence or absence of FEN (data not shown). Silencing of β2-AR with siRNA decreases proliferation as measured by CyQuant and 3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay compared with treatment with scrambled control (Online Figure IIIA-IIIC). Collectively, these results demonstrate an adrenergic-mediated proliferative response in CPCs via β2-AR stimulation.
The underlying molecular signaling resulting from FEN stimulation of CPCs was assessed in the presence or absence of ICI 118, 551. AKT and extracellular signal-regulated kinase 1/2 phosphorylation increases 3.7-fold and 3.3-fold, respectively, with FEN exposure that was blunted to only 1.4fold and 1.3-fold increases, respectively, with introduction of ICI 118, 551 ( Figure 2D and 2E) . Similarly, cyclin D1 levels significantly increase (P<0.01) 2.4-fold with FEN but only 1.4-fold with FEN+ICI 118, 551 compared with vehicletreated cells. Also, FEN-treated CPCs show a significant decrease (P<0.05) in G protein-coupled receptor kinase 2 (GRK2) levels compared with vehicle treatment ( Figure 2D and 2E), corroborating a report of decreased GRK2 levels with cell cycle progression. 29 GRK2 levels decrease 49% after FEN but remain elevated if exposed to both FEN and ICI 118, 551. β2-AR signaling in cardiomyocytes promotes protective signaling via an AKT/endothelial NO synthase (eNOS)dependent pathway 30 that can be blocked by pharmacological inhibition of PI3-K (LY-294002) or eNOS (L-NAME). Similar to cardiomyocytes, CPCs show significant increases in eNOS phosphorylation ( Figure 2F ) after FEN exposure (1.9-fold; P<0.01) that is abrogated by either LY294002 or L-NAME (0.5-fold and 0.7-fold, respectively). Although L-NAME has been shown to affect downstream eNOS signaling, recent published studies support a feedback mechanism of L-NAME, 31, 32 concurring with our findings of CPCs treated with FEN. Collectively, these results indicate that β2-AR activation promotes cardioprotective signaling in CPCs via the AKT/eNOS pathway in parallel with GRK2 downregulation.
CPCs Acquire β1-AR and Sensitize to Cell Death After Cardiogenic Commitment
Acquisition of a cardiomyocyte phenotype by CPCs inevitably leads to β1-AR expression as maturation progresses toward differentiation, which would correlate with sensitivity to adrenergic-induced cell death. Differentiation stimulus was provided by coculture of neonatal rat cardiomyocytes (NRCM) with CPCs modified to express enhanced GFP (CPCe) to allow fluorescent and immunohistochemical discrimination from NRCM. CPCe exposed to coculture show β1-AR expression concurrent with loss of c-kit as determined by immunocytochemistry ( Figure 3A ). In addition, CPCe express β2-AR ( Figure 3C ) after 7 days of coculture and are differentiated from myocytes on the basis of GFP and actinin expression ( Figure 3B ). β1-AR ( Figure 3D ) and cardiac troponin T ( Figure 3F ) mRNAs are detectable, whereas β2-AR mRNA levels decreased in CPCe ( Figure 3E ) after 7 days of coculture by quantitative reverse transcriptase polymerase chain reaction analysis using validated primers specific to mouse mRNA that do not recognize mRNA of NRCM (Online Figure IIIE-IIIG). Because undifferentiated CPCs do not express cardiac markers and our primers do not bind to rat mRNA, we believe that the cardiac marker expression for β1-AR, β2-AR, and cardiac troponin T may be related to differentiated CPCs. Conversely, selective inhibition of β2-AR by siRNA decreased expression of cardiac troponin T and β1-AR in siβ2-AR-treated CPCs (Online Figure IIID Figure 3H ). Participation of β1-AR is corroborated by a significant decrease in ISO-mediated cell death (8.7%; P<0.001) in the presence of metoprolol, a specific β1-AR antagonist. In the presence of ICI 118, 551, an antagonist of β2-AR, increased cell death (15.1%; Figure 3H ) was observed as ISO mediated its effect through enhanced β1-AR stimulation. In comparison, CPCs maintained alone without coculture show no cell death after treatment with ISO ( Figure  3G ). Furthermore, increased β2-AR mRNA levels were observed in CPCs in concordance with increased survival after commitment in the presence of ISO and metoprolol (Online Figure III I) . Similarly, increased β1-AR mRNA level was observed in committed CPCs after ISO and ICI 118, 551 correlating with decreased survival. To further clarify the effect of metoprolol on CPC survival and whether this is because of the inhibition of CPC differentiation, CPCs were cocultured with NRCMs in the presence of metoprolol. No significant change on CPC differentiation was observed in the presence of metoprolol, indicating that metoprolol does not affect CPC differentiation. In parallel, CPCs were adenovirally engineered to express β1-AR (Online Figure  IIIH) and subjected to ISO stress to assess β1-AR signaling effect on CPCs without even progressing to a cardiac phenotype. β1-AR-expressing CPCs show a significant increase in cell death (43%; P<0.001) compared with Figure 3I ), and this effect is significantly reduced in the presence of metoprolol (22.3%; P<0.001). CPC control infection with adenovirus-GFP shows nonsignificant effects on cell death after ISO treatment concurring with earlier results ( Figure 3G ). Collectively, these findings indicate that acquisition of β1-AR in the process of lineage commitment correlates with sensitization to adrenergic-induced cell death.
CPC Survival and Proliferation Are Enhanced by β-Blockade in the Failing Heart
Because adrenergic stimulation of cardiogenic CPCs promotes cell death after β1-AR acquisition (Figure 3) , the ability of metoprolol, a selective β1-AR blocker, to protect CPCe was examined in the context of heart failure. The TOT mouse model suffers from catecholamine-induced chronic dilated cardiomyopathy, preventable by administration of nonselective β-blockade. 33 Survival of adoptively transferred CPCe in the failing heart was assessed in TOT mice 2 weeks after delivery in the presence or absence of concurrent metoprolol treatment begun 4 weeks before CPCe delivery ( Figure 4A ). Presence of c-kit+ cells was examined by immunolabeling of myocardial sections to quantify populations of endogenous CPCs and donated CPCe. Metoprolol treatment yields a 3.1-fold increase in CPCe (c-kit+/GFP+) compared with vehicle-treated controls after 2 weeks of transplantation ( Figure 4B-4E ). In addition, increases in endogenous CPC populations (c-kit + /GFP − ) of L) in serum-free medium for 2 hours followed by 6 hours of recovery in full serum medium. CPCs kept in serum-free medium without FEN (0 µmol/L) for 2 hours and full serum (FM)-treated groups were used as controls (n=5). B, CyQuant assay. CPCs treated with FEN (1 µmol/L) show increased proliferation as measured by CyQuant assay compared with cells treated with β2-AR antagonist ICI 118, 551 (n=3). C, Metabolic activity increased in CPCs stimulated with FEN compared with cells treated with β2-AR antagonist (n=3). D and E, FEN treatment upregulates AKT phosphorylation, ERK phosphorylation, and cyclin D1 and downregulates G protein-coupled receptor kinase 2 (GRK2), whereas treatment with a β2-specific antagonist ICI 118, 551 blocks the effect of FEN stimulation. *P<0.05, **P<0.01, and ***P<0.001 significance for CPCs vs FEN; #P<0.05, ##P<0.01, and ###P<0.001 significance for FEN vs FEN+ICI 118, 551 (n=4). F, Increased endothelial NO synthase (eNOS) phosphorylation in FEN-treated CPCs blocked in the presence of LY294002 and L-NAME (n=3). *P<0.05, **P<0.01, and ***P<0.001 significance for CPCs vs FEN; #P<0.05, ##P<0.01, and ###P<0.001 significance for FEN vs FEN+LY-294002; and ɸP<0.05, ɸɸP<0.01, and ɸɸɸP<0.001 significance for FEN vs FEN+L-NAME. NS indicates nonsignificant.
3.9-fold were observed in hearts of CPCe/metoprolol-treated hearts, respectively, compared with the CPCe group without metoprolol ( Figure 4E ). Greater levels of CPCe proliferation are evident in hearts of mice treated with metoprolol confirmed by a 2.7-fold increase in c-kit+/proliferating cell nuclear antigen-positive cells in metoprolol-treated mice compared with vehicle-treated CPCe controls (Online Figure  IVA-IVC) . Furthermore, CPCs treated with metoprolol for 7 days showed no significant changes in cardiac differentiation markers, ruling out a direct role for metoprolol on CPC differentiation. Collectively, these results support the postulate that selective β1-AR blockade augments CPC survival and proliferation in the failing myocardium.
Increased Survival of β1-Expressing Cells in Failing Hearts With β-Blockade
CPC survival and proliferation are increased in failing hearts with β-blockade (Figure 4) , supporting expansion of the resident CPC pool (Figure 4) while increasing the number of committed cells in failing hearts. Acquisition of β1-AR on CPCs is representative of a committed state because c-kit+ CPCs do not express these receptors (Figures 1 and 3) . Analysis of CPCetransplanted TOT hearts with metoprolol treatment revealed .01, and ###P<0.001 significance for CPC ISO vs CPC ISO/metoprolol; and ɸP<0.05, ɸɸP<0.01, and ɸɸɸP<0.001 significance for CPC ISO/metoprolol vs CPC ISO/ ICI 118, 551 (n=3). I, CPCs infected with adenovirus (Ad)-β1-AR and treated with ISO show increased cell death as measured by FACS analysis compared with metoprolol-treated CPCs and vehicle-treated controls (n=3). In parallel, AdGFP CPCs showed no effect of ISO-induced stress. *P<0.05, **P<0.01, and ***P<0.001 significance for Ad-β1-AR NT vs Ad-β1-AR CPCs ISO; #P<0.05, ##P<0.01, and ###P<0.001 significance for Ad-β1-AR CPCs ISO vs Ad-β1-AR CPCs ISO/metoprolol. February 1, 2013 significantly more CPCe-expressing β1-AR colocalized with GFP (7.0%) compared with vehicle-treated hearts (1.9%; Figure 5A -5C), indicating increased CPC commitment and survival of myocyte precursors. Similarly, increased β2-AR expression on CPCe was observed in TOT hearts with metoprolol (15.7%) compared with hearts with vehicle-treated controls (3.7%; Figure 5D -5F). In summary, these results indicate that β-blockade leads to enhanced survival of committed CPCs and protection from deleterious effects of β1-AR-mediated signaling, thereby allowing for CPC support of myocardial repair.
Beneficial Effects of Long-term β1-AR Blockade Include Reduction of Cardiomyocyte Apoptosis and DNA Synthesis in Failing Hearts
Consistent with expected salutary effects of β1-AR blockade, heart: body weight ratio is significantly (P<0.05) decreased by 50% in metoprolol-treated group (Online Figure VA) concurrent with decreased myocyte cross-sectional area compared with vehicle-treated controls (Online Figure VB and VC). Long-term metoprolol treatment of TOT mice for 6 weeks augmented cardiac function measured by echocardiography after 6 weeks, showing 1.7-fold and 1.9fold increases in ejection fraction and fractional shortening, respectively, compared with vehicle-treated controls (Online Figure VD and VE) , whereas no significant change in cardiac function was observed in metoprolol-treated animals (data not shown). Serum levels of epinephrine and norepinephrine were significantly reduced (P<0.001 and P<0.001, respectively) in hearts treated with metoprolol compared with vehicle-treated controls (Online Figure VI) . Cardiotoxicity of chronic catecholamine storm in heart failure leads to a vicious cycle of cardiomyocyte death and proliferation 34, 35 that is interrupted by β1-AR blockade. Metoprolol treatment of TOT mice for 6 weeks leads to significant reduction in cardiomyocyte BrdU+ labeling (39% decrease; P<0.01; Online Figure VIIA-VIIC) and terminal deoxynucleotidyl transferase dUTP nick end labeling+ cells (48% decrease; P<0.05) relative to vehicle-treated controls (Online Figure  VIID-VIIF) . Collectively, these results show metoprololmediated amelioration of cardiomyocyte stress that together validates the efficacy of the 6-week treatment protocol.
Discussion
β-adrenergic signaling is an integral part of cardiac adaptation to physiological demands of cardiac development, as well as acute or pathological stress, 15, 16 but consequences of adrenergic drive on CPC populations have been previously overlooked. Pathological adrenergic overdrive leads to receptor desensitization that eventually becomes cardiotoxic, 18, 36 resulting in cardiomyocyte death. 36 However, norepinephrine release within bone marrow in cases of stress, inflammation, and tissue repair coincides with increased numbers of progenitors released into the blood circulation. 37, 38 Similarly, our findings support the concept that catecholamine signaling is beneficial in priming CPCs for response to pathological injury, although simultaneously exerting proapoptotic action on mature myocytes and myocyte precursors upon acquisition of β1-AR expression.
Without pharmacological intervention, the failing heart labors under a catecholamine storm that promotes adrenergic desensitization. β-blockers resensitize the heart toward β-AR signaling associated with improvement in systolic function and regression in myocardial mass. [39] [40] [41] Although β-blockers are an effective clinical interventional therapy for treatment of failing hearts, relative contributions of underlying mechanisms for salutary effects remain a subject of open debate: myocardial neovascularization, 42 antioxidant properties, 43 and improvement of calcium signaling 44 have all been posed as previous explanations. Biological potentiation of CPCs can now be added to this growing list of mechanistic underpinnings of β-blockade, consistent with recent reports of enhanced endothelial progenitor cell activation 42 and increased cycling of cardiogenic cells. 45 The molecular basis of adrenergic stimulation in CPCs rests with differential expression of β2-AR, but not β1-AR, that can be considered an uncommitted state coincident with c-kit+ expression ( Figure 1 ). Although we observed decreased β2-AR However, signaling through the β-adrenergic system becomes negative at the level of mature cardiomyocyte (red arrows) that expresses both β-receptors, leading to myocyte apoptosis and necrosis. β-blockade protects cardiomyocytes from activated β-adrenergic signaling and enhances cardiomyocyte survival that feedbacks onto preserving CPC population. Persistent cardiomyocyte injury leads to CPC activation and commitment, yet simultaneously kills the newly formed myocytes leading to vicious cycle resulting in exhaustion and depletion of the CPC pool within failing hearts. February 1, 2013 expression in the oldest human patient (84 years), to relate β2-AR expression with age, additional age-matched samples with similar disease causes will be required. Furthermore, uncommitted CPCs actually proliferate in response to adrenergic drive that depends on β2-AR and correlates with salutary AKT/ eNOS phosphorylation (Figure 2 ). Recent reports demonstrate that both β1-AR and β2-AR couple to the same downstream effectors, such as GRK, regulator of G protein signaling, and so on. [46] [47] [48] [49] Induction of CPC differentiation by coculture with NRCMs leads to β1-AR acquisition ( Figure 3A-3E) , consistent with a mature cardiomyocyte phenotype. 21 However, once placed in coculture conditions where β1-AR is induced, CPCs now become sensitized to adrenergic stimulation that promotes cell death (Figure 3 ). Adrenergic stimulation mediates CPC survival and proliferation through differential expression of β-ARs that is altered by β1-specific blockade (Figure 4) . Importantly, β1-blockade promotes survival of β1-AR+ CPCs, representative of a committed CPC state ( Figure  5 ). The selection of β1-blockade with metoprolol over nonselective β-antagonism is based on the premise that inhibiting deleterious β1-AR signaling protects CPCs once they become committed and express β1-AR but concomitantly promotes β2-AR signaling leading to increased CPC activation and expansion. Carvedilol is a superior β-blocker than metoprolol with known α1-AR blocking, antioxidant, 43 and calcium signaling 44 properties in addition to β1-blockade. Because metoprolol is highly specific for β1-AR with no known affinities for other ARs, it represents a better choice to study the differential role of β1-AR on CPC survival versus cell death. It will be interesting to look at the effects of carvedilol treatment on CPC survival in the future, in combination with the role of other ARs and β-ARs. Furthermore, nonspecific β-blockade would impart CPC protection from β1-AR signaling but also limit β2-AR-mediated CPC proliferation. The transition to β1-AR sensitization in the process of lineage specification may provide an important clue for the long-term beneficial effect of β-adrenergic blockade, which in addition to existing cardiomyocyte salvage also allows for improvement of CPC persistence. It is tempting to speculate that the refractory nature of some patients to palliative β-adrenergic blockade may rest with an impaired endogenous CPC population suffering from exhaustion as a result of age, senescence, or chronic stress that incapacitates their cardiogenic potential but requires further validation. Future studies will be needed to assess whether functionally compromised stem cells can be restored by additional interventional approaches in conjunction with β-adrenergic blockade.
The beneficial effects of β-adrenergic blockade in the failing heart are clearly dependent on protection of existing cardiomyocytes from apoptotic stimulation and, based on our findings, may also include potentiation of CPC expansion and survival. Recent evidence supports myocardial regeneration in the heart by activation and commitment of CPCs and a hierarchical organization of their progeny, 50 with acquisition of myocyte phenotype as a consequence of sequential generation of various intermediate myocyte precursors and progenitors. Furthermore, sequential expression of β-ARs on CPCs expressing c-kit provides the basis for a disparate cellular response in the face of activated adrenergic signaling ( Figure  6 ). β-adrenergic signaling induces proliferation in CPCs mediated by β2-AR, whereas β-adrenergic signaling becomes proapoptotic in the β1-AR expressing committed CPCs. Furthermore, CPCs do not express β1-AR in an uncommitted state, so β1-AR blockade does not affect β2-AR-mediated CPC expansion. β1-AR-specific blockade protects existing myocytes from chronic β1-AR stimulation, augmenting the cardiac milieu and initiating a positive feedback loop for CPCs increasing survival, and is not related to block or inhibition of CPC differentiation (Figure 6 ). Age and disease can lead to a significant loss of myocyte reserve within the heart promoting release of paracrine factors 21 and activation of signaling cascades 50 affecting CPC-mediated reparability. Collectively, adrenergic signaling promotes CPC activation and proliferation in β2-AR-dependent manner, and β1-blockade improves the cardiac environment allowing CPC expansion, proliferation, and acquisition of a committed cardiogenic state. Furthermore, ongoing β1-AR blockade after cardiac commitment prevents catecholamine-induced cell death of lineage committed CPCs ( Figure 6 ) to enhance persistence and engraftment. Reduced β1-AR apoptotic signaling allowing β2-AR to promote prosurvival and proliferation responses improves cardiac function after combined therapy with β2-agonist and β1-blocker, 51 potentially as alternate combinatorial therapy for congestive heart failure. 52 Synergistic β2-AR stimulation and β1-AR blockade together may be efficacious for CPC expansion in the failing heart, potentially paving the way for a novel therapeutic modality to treat congestive heart failure.
